OtherConsensus

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Ping Li, Yang Liu, Yun Liang, Jian Bo, Sujun Gao, Yongxian Hu, Yu Hu, He Huang, Xiaojun Huang, Hongmei Jing, Xiaoyan Ke, Jianyong Li, Yuhua Li, Qifa Liu, Peihua Lu, Heng Mei, Ting Niu, Yongping Song, Yuqin Song, Liping Su, Sanfang Tu, Jianxiang Wang, Depei Wu, Zhao Wang, Kailin Xu, Zhitao Ying, Qingming Yang, Yajing Zhang, Fengxia Shi, Bin Zhang, Huilai Zhang, Xi Zhang, Mingfeng Zhao, Weili Zhao, Xiangyu Zhao, Liang Huang, Jun Zhu, Wenbin Qian, Weidong Han and Aibin Liang
Cancer Biology & Medicine February 2023, 20 (2) 129-146; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0585

References

  1. 1.↵
    2. Grigor EJM,
    3. Fergusson D,
    4. Kekre N,
    5. Montroy J,
    6. Atkins H,
    7. Seftel MD, et al.
    Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019; 33: 98–110.
    OpenUrlPubMed
  2. 2.
    2. Chavez JC,
    3. Locke FL.
    CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol. 2018; 31: 135–46.
    OpenUrl
  3. 3.↵
    2. Minghan Q,
    3. Shan W,
    4. Xinrui C,
    5. Huaqing W.
    Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting. Cancer Biol Med. 2022; 19: 1117–20.
    OpenUrlFREE Full Text
  4. 4.↵
    2. Wei J,
    3. Guo Y,
    4. Wang Y,
    5. Wu Z,
    6. Bo J,
    7. Zhang B, et al.
    Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021; 18: 792–804.
    OpenUrlCrossRef
  5. 5.
    2. Reagan PM,
    3. Friedberg JW.
    Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncol. 2021; 17: 1269–83.
    OpenUrl
  6. 6.
    2. Hayden PJ,
    3. Roddie C,
    4. Bader P,
    5. Basak GW,
    6. Bonig H,
    7. Bonini C, et al.
    Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33: 259–75.
    OpenUrl
  7. 7.↵
    2. Nuvvula S,
    3. Dahiya S,
    4. Patel SA.
    The novel therapeutic landscape for relapsed/refractory diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022; 22: 362–72.
    OpenUrl
  8. 8.↵
    2. Neelapu SS,
    3. Locke FL,
    4. Bartlett NL,
    5. Lekakis LJ,
    6. Miklos DB,
    7. Jacobson CA, et al.
    Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377: 2531–44.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Ying Z,
    3. Yang H,
    4. Guo Y,
    5. Li W,
    6. Zou D,
    7. Zhou D, et al.
    Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021; 10: 999–1011.
    OpenUrl
  10. 10.↵
    2. Zhu H,
    3. Deng H,
    4. Mu J,
    5. Lyu C,
    6. Jiang Y,
    7. Deng Q.
    Anti-CD22 CAR-T cell therapy as a salvage treatment in B cell malignancies refractory or relapsed after anti-CD19 CAR-T therapy. Onco Targets Ther. 2021; 14: 4023–37.
    OpenUrl
  11. 11.
    2. Zhang WY,
    3. Wang Y,
    4. Guo YL,
    5. Dai HR,
    6. Yang QM,
    7. Zhang YJ, et al.
    Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther. 2016; 1: 16002.
  12. 12.↵
    2. Deng W,
    3. Chen P,
    4. Lei W,
    5. Xu Y,
    6. Xu N,
    7. Pu JJ, et al.
    CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. Cancer Commun (Lond). 2021; 41: 925–9.
    OpenUrl
  13. 13.↵
    2. Tong C,
    3. Zhang Y,
    4. Liu Y,
    5. Ji X,
    6. Zhang W,
    7. Guo Y, et al.
    Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020; 136: 1632–44.
    OpenUrlCrossRefPubMed
  14. 14.
    2. Zhang Y,
    3. Wang Y,
    4. Liu Y,
    5. Tong C,
    6. Wang C,
    7. Guo Y, et al.
    Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial. Leukemia. 2022; 36: 189–96.
    OpenUrlCrossRef
  15. 15.↵
    2. Tu S,
    3. Zhou X,
    4. Guo Z,
    5. Huang R,
    6. Yue C,
    7. He Y, et al.
    CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma. Front Oncol. 2019; 9: 1350.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Sang W,
    3. Shi M,
    4. Yang J,
    5. Cao J,
    6. Xu L,
    7. Yan D, et al.
    Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020; 9: 5827–38.
    OpenUrl
  17. 17.
    2. Zeng C,
    3. Cheng J,
    4. Li T,
    5. Huang J,
    6. Li C,
    7. Jiang L, et al.
    Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020; 22: 166–71.
    OpenUrl
  18. 18.↵
    2. Cao Y,
    3. Xiao Y,
    4. Wang N,
    5. Wang G,
    6. Huang L,
    7. Hong Z, et al.
    CD19/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2021; 27: 910.e1–11.
    OpenUrl
  19. 19.↵
    2. Los-Arcos I,
    3. Iacoboni G,
    4. Aguilar-Guisado M,
    5. Alsina-Manrique L,
    6. Díaz de Heredia C,
    7. Fortuny-Guasch C, et al.
    Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021; 49: 215–31.
    OpenUrl
  20. 20.
    2. Schmidts A,
    3. Wehrli M,
    4. Maus MV.
    Toward better understanding and management of CAR-T cell-associated toxicity. Annu Rev Med. 2021; 72: 365–82.
    OpenUrl
  21. 21.↵
    2. Hill JA,
    3. Seo SK.
    How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020; 136: 925–35.
    OpenUrlPubMed
  22. 22.↵
    2. Han L,
    3. Zhou J,
    4. Li L,
    5. Zhou K,
    6. Zhao L,
    7. Zhu X, et al.
    Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies. Cancer Biol Med. 2021; 18: 1066–79.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Yang X,
    3. Wang GX,
    4. Zhou JF.
    CAR T cell therapy for hematological malignancies. Curr Med Sci. 2019; 39: 874–82.
    OpenUrl
  24. 24.
    2. Holstein SA,
    3. Lunning MA.
    CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020; 107: 112–22.
    OpenUrl
  25. 25.
    2. Huang R,
    3. Li X,
    4. He Y,
    5. Zhu W,
    6. Gao L,
    7. Liu Y, et al.
    Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020; 13: 86.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Specialty Committee of Biotherapy tCRHA. Experts consensus on clinical management of toxicity associated with CAR T cell therapy in non-Hodgkin’s lymphoma (NHL). Transl Med. 2021; 10: 1–11.
    OpenUrl
  27. 27.↵
    2. Wei J,
    3. Liu Y,
    4. Wang C,
    5. Zhang Y,
    6. Tong C,
    7. Dai G, et al.
    The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020; 5: 134.
    OpenUrl
  28. 28.↵
    2. Schuster SJ,
    3. Maziarz RT,
    4. Rusch ES,
    5. Li J,
    6. Signorovitch JE,
    7. Romanov VV, et al.
    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020; 4: 1432–9.
    OpenUrlPubMed
  29. 29.↵
    2. Lee DW,
    3. Santomasso BD,
    4. Locke FL,
    5. Ghobadi A,
    6. Turtle CJ,
    7. Brudno JN, et al.
    ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25: 625–38.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Neelapu SS,
    3. Tummala S,
    4. Kebriaei P,
    5. Wierda W,
    6. Gutierrez C,
    7. Locke FL, et al.
    Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15: 47–62.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Oken MM,
    3. Creech RH,
    4. Tormey DC,
    5. Horton J,
    6. Davis TE,
    7. McFadden ET, et al.
    Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649–55.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    2. Brepoels L,
    3. Stroobants S,
    4. De Wever W,
    5. Spaepen K,
    6. Vandenberghe P,
    7. Thomas J, et al.
    Aggressive and indolent non-Hodgkin’s lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma. 2007; 48: 1522–30.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    2. Frey N,
    3. Porter D.
    Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019; 25: e123–7.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Cobb DA,
    3. Lee DW.
    Cytokine release syndrome biology and management. Cancer J. 2021; 27: 119–25.
    OpenUrlPubMed
  35. 35.↵
    2. Abramson JS,
    3. Palomba ML,
    4. Gordon LI,
    5. Lunning MA,
    6. Wang M,
    7. Arnason J, et al.
    Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396: 839–52.
    OpenUrlCrossRefPubMed
  36. 36.↵
    2. Schuster SJ,
    3. Bishop MR,
    4. Tam CS,
    5. Waller EK,
    6. Borchmann P,
    7. McGuirk JP, et al.
    Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380: 45–56.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Giavridis T,
    3. van der Stegen SJC,
    4. Eyquem J,
    5. Hamieh M,
    6. Piersigilli A,
    7. Sadelain M.
    CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24: 731–8.
    OpenUrlCrossRefPubMed
  38. 38.↵
    2. Norelli M,
    3. Camisa B,
    4. Barbiera G,
    5. Falcone L,
    6. Purevdorj A,
    7. Genua M, et al.
    Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24: 739–48.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Hay KA,
    3. Hanafi LA,
    4. Li D,
    5. Gust J,
    6. Liles WC,
    7. Wurfel MM, et al.
    Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017; 130: 2295–306.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    2. Staedtke V,
    3. Bai RY,
    4. Kim K,
    5. Darvas M,
    6. Davila ML,
    7. Riggins GJ, et al.
    Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018; 564: 273–7.
    OpenUrlPubMed
  41. 41.↵
    2. Liu Y,
    3. Fang Y,
    4. Chen X,
    5. Wang Z,
    6. Liang X,
    7. Zhang T, et al.
    Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020; 5: eaax7969.
  42. 42.↵
    2. Wagner DH Jr.,
    3. Stout RD,
    4. Suttles J.
    Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol. 1994; 24: 3148–54.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    2. McInnes IB,
    3. Leung BP,
    4. Sturrock RD,
    5. Field M,
    6. Liew FY.
    Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med. 1997; 3: 189–95.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    2. Avice MN,
    3. Sarfati M,
    4. Triebel F,
    5. Delespesse G,
    6. Demeure CE.
    Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol. 1999; 162: 2748–53.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    2. Birkland TP,
    3. Sypek JP,
    4. Wyler DJ.
    Soluble TNF and membrane TNF expressed on CD4+ T lymphocytes differ in their ability to activate macrophage antileishmanial defense. J Leukoc Biol. 1992; 51: 296–9.
    OpenUrlPubMedWeb of Science
  46. 46.↵
    2. Mirza AS,
    3. Kumar A,
    4. Hashmi H,
    5. Garcia F,
    6. Logothetis CN,
    7. Darwin A, et al.
    Incidence and management of effusions before and after CD19-directed chimeric antigen receptor (CAR) T cell therapy in large B cell lymphoma. Transplant Cell Ther. 2021; 27: 242.e1–6.
    OpenUrl
  47. 47.↵
    2. Zahid A,
    3. Siegler EL,
    4. Kenderian SS.
    CART cell toxicities: new insight into mechanisms and management. Clin Hematol Int. 2020; 2: 149–55.
    OpenUrl
  48. 48.
    2. Xiao X,
    3. Huang S,
    4. Chen S,
    5. Wang Y,
    6. Sun Q,
    7. Xu X, et al.
    Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021; 40: 367.
    OpenUrl
  49. 49.↵
    2. Cosenza M,
    3. Sacchi S,
    4. Pozzi S.
    Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021; 22: 7652.
    OpenUrl
  50. 50.↵
    2. Qian WB,
    3. Liu H.
    How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management. Chin J Hematol. 2022; 43: 197–202.
    OpenUrl
  51. 51.↵
    2. Brudno JN,
    3. Kochenderfer JN.
    Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127: 3321–30.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    2. Cortes-Bullich A,
    3. Perez A,
    4. Bachmeier C,
    5. Mhaskar R,
    6. Chavez JC,
    7. Shah B, et al.
    Outcomes of CD19 chimeric antigen receptor T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma. Transplant Cell Ther. 2021; 27: 768.e1–6.
    OpenUrl
  53. 53.↵
    2. Hu Y,
    3. Wang J,
    4. Pu C,
    5. Zhao K,
    6. Cui Q,
    7. Wei G, et al.
    Delayed terminal ileal perforation in a relapsed/refractory B-cell lymphoma patient with rapid remission following chimeric antigen receptor T-cell therapy. Cancer Res Treat. 2018; 50: 1462–6.
    OpenUrl
  54. 54.↵
    2. Alvi RM,
    3. Frigault MJ,
    4. Fradley MG,
    5. Jain MD,
    6. Mahmood SS,
    7. Awadalla M, et al.
    Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019; 74: 3099–108.
    OpenUrlFREE Full Text
  55. 55.↵
    2. Burns EA,
    3. Gentille C,
    4. Trachtenberg B,
    5. Pingali SR,
    6. Anand K.
    Cardiotoxicity associated with anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy: recognition, risk factors, and management. Diseases. 2021; 9: 20.
    OpenUrl
  56. 56.↵
    2. Catino AB.
    Cytokines are at the heart of it: cytokine release syndrome underlies cardiovascular effects of CAR T cell. JACC CardioOncol. 2020; 2: 204–6.
    OpenUrl
  57. 57.
    2. Simbaqueba CC,
    3. Aponte MP,
    4. Kim P,
    5. Deswal A,
    6. Palaskas NL,
    7. Iliescu C, et al.
    Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias. J Immunother Precis Oncol. 2020; 3: 113–20.
    OpenUrl
  58. 58.↵
    2. Steiner RE,
    3. Banchs J,
    4. Koutroumpakis E,
    5. Becnel M,
    6. Gutierrez C,
    7. Strati P, et al.
    Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022; 107: 1555–66.
    OpenUrl
  59. 59.↵
    2. Cordeiro A,
    3. Bezerra ED,
    4. Hirayama AV,
    5. Hill JA,
    6. Wu QV,
    7. Voutsinas J, et al.
    Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020; 26: 26–33.
    OpenUrlCrossRefPubMed
  60. 60.↵
    2. Porter D,
    3. Frey N,
    4. Wood PA,
    5. Weng Y,
    6. Grupp SA.
    Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018; 11: 35.
    OpenUrlCrossRefPubMed
  61. 61.↵
    2. Chou CK,
    3. Turtle CJ.
    Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 2020; 20: 653–64.
    OpenUrl
  62. 62.↵
    2. Jain T,
    3. Knezevic A,
    4. Pennisi M,
    5. Chen Y,
    6. Ruiz JD,
    7. Purdon TJ, et al.
    Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4: 3776–87.
    OpenUrlCrossRefPubMed
  63. 63.↵
    2. Schubert ML,
    3. Schmitt M,
    4. Wang L,
    5. Ramos CA,
    6. Jordan K,
    7. Müller-Tidow C, et al.
    Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021; 32: 34–48.
    OpenUrlCrossRefPubMed
  64. 64.↵
    2. Ying Z,
    3. Huang XF,
    4. Xiang X,
    5. Liu Y,
    6. Kang X,
    7. Song Y, et al.
    A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019; 25: 947–53.
    OpenUrlCrossRefPubMed
  65. 65.↵
    2. Takao M.
    Neurotoxicities associated with CAR-T cell therapy. Brain Nerve. 2021; 73: 47–58.
    OpenUrl
  66. 66.↵
    2. Cornillon J,
    3. Hadhoum N,
    4. Roth-Guepin G,
    5. Quessar A,
    6. Platon L,
    7. Ouachée-Chardin M, et al.
    Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: recommendations of the French Society of bone marrow transplantation and cellular therapy (SFGM-TC). Bull Cancer. 2020; 107: S12–7.
    OpenUrl
  67. 67.↵
    2. Parker KR,
    3. Migliorini D,
    4. Perkey E,
    5. Yost KE,
    6. Bhaduri A,
    7. Bagga P, et al.
    Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020; 183: 126–42.e17.
    OpenUrlCrossRefPubMed
  68. 68.↵
    2. Westin JR,
    3. Kersten MJ,
    4. Salles G,
    5. Abramson JS,
    6. Schuster SJ,
    7. Locke FL, et al.
    Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021; 96: 1295–312.
    OpenUrlCrossRef
  69. 69.
    2. Cao JX,
    3. Wang H,
    4. Gao WJ,
    5. You J,
    6. Wu LH,
    7. Wang ZX.
    The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020; 22: 214–26.
    OpenUrl
  70. 70.↵
    2. Locke FL,
    3. Ghobadi A,
    4. Jacobson CA,
    5. Miklos DB,
    6. Lekakis LJ,
    7. Oluwole OO, et al.
    Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20: 31–42.
    OpenUrlCrossRefPubMed
  71. 71.↵
    2. Hunter BD,
    3. Jacobson CA.
    CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019; 111: 646–54.
    OpenUrlPubMed
  72. 72.↵
    2. Karschnia P,
    3. Jordan JT,
    4. Forst DA,
    5. Arrillaga-Romany IC,
    6. Batchelor TT,
    7. Baehring JM, et al.
    Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019; 133: 2212–21.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    2. Freyer CW,
    3. Porter DL.
    Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020; 146: 940–8.
    OpenUrlCrossRefPubMed
  74. 74.↵
    2. Yan Z,
    3. Cao J,
    4. Cheng H,
    5. Qiao J,
    6. Zhang H,
    7. Wang Y, et al.
    A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019; 6: e521–9.
    OpenUrlPubMed
  75. 75.↵
    2. Brudno JN,
    3. Kochenderfer JN.
    Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019; 34: 45–55.
    OpenUrlPubMed
  76. 76.↵
    2. Al-Samkari H,
    3. Berliner N.
    Hemophagocytic lymphohistiocytosis. Annu Rev Pathol. 2018; 13: 27–49.
    OpenUrlCrossRefPubMed
  77. 77.
    2. Griffin G,
    3. Shenoi S,
    4. Hughes GC.
    Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020; 34: 101515.
  78. 78.↵
    2. Sandler RD,
    3. Tattersall RS,
    4. Schoemans H,
    5. Greco R,
    6. Badoglio M,
    7. Labopin M, et al.
    Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP). Front Immunol. 2020; 11: 524.
    OpenUrlCrossRefPubMed
  79. 79.↵
    2. Shalabi H,
    3. Gust J,
    4. Taraseviciute A,
    5. Wolters PL,
    6. Leahy AB,
    7. Sandi C, et al.
    Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021; 18: 363–78.
    OpenUrl
  80. 80.↵
    2. Maude SL,
    3. Barrett D,
    4. Teachey DT,
    5. Grupp SA.
    Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014; 20: 119–22.
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    2. Teachey DT,
    3. Lacey SF,
    4. Shaw PA,
    5. Melenhorst JJ,
    6. Maude SL,
    7. Frey N, et al.
    Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016; 6: 664–79.
    OpenUrlAbstract/FREE Full Text
  82. 82.↵
    2. Ramos-Casals M,
    3. Brito-Zerón P,
    4. López-Guillermo A,
    5. Khamashta MA,
    6. Bosch X.
    Adult haemophagocytic syndrome. Lancet. 2014; 383: 1503–16.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.
    2. Lichtenstein DA,
    3. Schischlik F,
    4. Shao L,
    5. Steinberg SM,
    6. Yates B,
    7. Wang HW, et al.
    Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021; 138: 2469–84.
    OpenUrlCrossRefPubMed
  84. 84.↵
    2. Brisse E,
    3. Matthys P,
    4. Wouters CH.
    Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016; 174: 175–87.
    OpenUrl
  85. 85.↵
    2. Fried S,
    3. Avigdor A,
    4. Bielorai B,
    5. Meir A,
    6. Besser MJ,
    7. Schachter J, et al.
    Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54: 1643–50.
    OpenUrlCrossRefPubMed
  86. 86.↵
    2. Schaefer A,
    3. Huang Y,
    4. Kittai A,
    5. Maakaron JE,
    6. Saygin C,
    7. Brammer J, et al.
    Cytopenias after CD19 chimeric antigen receptor T-cells (CAR-T) therapy for diffuse large B-cell lymphomas or transformed follicular lymphoma: a single institution experience. Cancer Manag Res. 2021; 13: 8901–6.
    OpenUrlCrossRefPubMed
  87. 87.↵
    2. Brudno JN,
    3. Natrakul D,
    4. Lam N,
    5. Dulau-Florea A,
    6. Yuan CM,
    7. Kochenderfer JN.
    Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. Leuk Lymphoma. 2022; 63: 1849–60.
    OpenUrl
  88. 88.↵
    2. Locke FL,
    3. Miklos DB,
    4. Jacobson CA,
    5. Perales MA,
    6. Kersten MJ,
    7. Oluwole OO, et al.
    Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386: 640–54.
    OpenUrlCrossRefPubMed
  89. 89.↵
    2. Schuster SJ,
    3. Tam CS,
    4. Borchmann P,
    5. Worel N,
    6. McGuirk JP,
    7. Holte H, et al.
    Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22: 1403–15.
    OpenUrlCrossRef
  90. 90.↵
    2. Hill JA,
    3. Li D,
    4. Hay KA,
    5. Green ML,
    6. Cherian S,
    7. Chen X, et al.
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018; 131: 121–30.
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    2. Gudiol C,
    3. Lewis RE,
    4. Strati P,
    5. Kontoyiannis DP.
    Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 2021; 8: e216–28.
    OpenUrlPubMed
  92. 92.↵
    2. Maude SL,
    3. Frey N,
    4. Shaw PA,
    5. Aplenc R,
    6. Barrett DM,
    7. Bunin NJ, et al.
    Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507–17.
    OpenUrlCrossRefPubMedWeb of Science
  93. 93.↵
    2. Kochenderfer JN,
    3. Dudley ME,
    4. Feldman SA,
    5. Wilson WH,
    6. Spaner DE,
    7. Maric I, et al.
    B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119: 2709–20.
    OpenUrlAbstract/FREE Full Text
  94. 94.↵
    2. Lee DW,
    3. Gardner R,
    4. Porter DL,
    5. Louis CU,
    6. Ahmed N,
    7. Jensen M, et al.
    Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124: 188–95.
    OpenUrlAbstract/FREE Full Text
  95. 95.↵
    2. Li P,
    3. Zhou L,
    4. Ye S,
    5. Zhang W,
    6. Wang J,
    7. Tang X, et al.
    Risk of HBV reactivation in patients with resolved HBV infection receiving anti-CD19 chimeric antigen receptor T cell therapy without antiviral prophylaxis. Front Immunol. 2021; 12: 638678.
  96. 96.↵
    2. Kusumoto S,
    3. Tobinai K.
    Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematol Am Soc Hematol Educ Program. 2014; 2014: 576–83.
    OpenUrl
  97. 97.↵
    2. Haidar G,
    3. Garner W,
    4. Hill JA.
    Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. Curr Opin Infect Dis. 2020; 33: 449–57.
    OpenUrl
  98. 98.↵
    2. Link H,
    3. Böhme A,
    4. Cornely OA,
    5. Höffken K,
    6. Kellner O,
    7. Kern WV, et al.
    Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003; 82 Suppl 2: S105–17.
    OpenUrlCrossRefPubMedWeb of Science
  99. 99.↵
    2. Kampouri E,
    3. Walti CS,
    4. Gauthier J,
    5. Hill JA.
    Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022; 15: 305–20.
    OpenUrl
  100. 100.↵
    2. Juluri KR,
    3. Wu QV,
    4. Voutsinas J,
    5. Hou J,
    6. Hirayama AV,
    7. Mullane E, et al.
    Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022; 6: 2055–68.
    OpenUrl
  101. 101.↵
    2. Gupta A,
    3. Moore JA.
    Tumor lysis syndrome. JAMA Oncol. 2018; 4: 895.
    OpenUrl
  102. 102.↵
    2. Howard SC,
    3. Jones DP,
    4. Pui CH.
    The tumor lysis syndrome. N Engl J Med. 2011; 364: 1844–54.
    OpenUrlCrossRefPubMedWeb of Science
  103. 103.↵
    2. Rahmani B,
    3. Patel S,
    4. Seyam O,
    5. Gandhi J,
    6. Reid I,
    7. Smith N, et al.
    Current understanding of tumor lysis syndrome. Hematol Oncol. 2019; 37: 537–47.
    OpenUrlPubMed
  104. 104.↵
    2. Coiffier B,
    3. Altman A,
    4. Pui CH,
    5. Younes A,
    6. Cairo MS.
    Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26: 2767–78.
    OpenUrlAbstract/FREE Full Text
  105. 105.↵
    2. Muslimani A,
    3. Chisti MM,
    4. Wills S,
    5. Nadeau L,
    6. Zakalik D,
    7. Daw H, et al.
    How we treat tumor lysis syndrome. Oncology (Williston Park). 2011; 25: 369–75.
    OpenUrl
  106. 106.↵
    2. Esmaeilzadeh A,
    3. Tahmasebi S,
    4. Athari SS.
    Chimeric antigen receptor-T cell therapy: applications and challenges in treatment of allergy and asthma. Biomed Pharmacother. 2020; 123: 109685.
  107. 107.↵
    2. Zhang WY,
    3. Liu Y,
    4. Wang Y,
    5. Nie J,
    6. Guo YL,
    7. Wang CM, et al.
    Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. Gene Ther. 2018; 25: 198–204.
    OpenUrl
  108. 108.↵
    2. Cappell KM,
    3. Sherry RM,
    4. Yang JC,
    5. Goff SL,
    6. Vanasse DA,
    7. McIntyre L, et al.
    Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020; 38: 3805–15.
    OpenUrlCrossRefPubMed
  109. 109.↵
    2. Friedberg JW,
    3. Neuberg D,
    4. Stone RM,
    5. Alyea E,
    6. Jallow H,
    7. LaCasce A, et al.
    Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1999; 17: 3128–35.
    OpenUrlAbstract/FREE Full Text
  110. 110.
    2. Tward JD,
    3. Wendland MM,
    4. Shrieve DC,
    5. Szabo A,
    6. Gaffney DK.
    The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006; 107: 108–15.
    OpenUrlCrossRefPubMedWeb of Science
  111. 111.
    2. Travis LB,
    3. Curtis RE,
    4. Glimelius B,
    5. Holowaty E,
    6. Van Leeuwen FE,
    7. Lynch CF, et al.
    Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1993; 85: 1932–7.
    OpenUrlCrossRefPubMedWeb of Science
  112. 112.
    2. Major A,
    3. Smith DE,
    4. Ghosh D,
    5. Rabinovitch R,
    6. Kamdar M.
    Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. Cancer. 2020; 126: 189–201.
    OpenUrlPubMed
  113. 113.↵
    2. Liu Y,
    3. Bewersdorf JP,
    4. Stahl M,
    5. Zeidan AM.
    Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 2019; 34: 67–83.
    OpenUrlCrossRef
  114. 114.↵
    2. Pirani M,
    3. Marcheselli R,
    4. Marcheselli L,
    5. Bari A,
    6. Federico M,
    7. Sacchi S.
    Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis. Ann Oncol. 2011; 22: 1845–58.
    OpenUrlCrossRefPubMedWeb of Science
  115. 115.↵
    2. Morton LM,
    3. Curtis RE,
    4. Linet MS,
    5. Bluhm EC,
    6. Tucker MA,
    7. Caporaso N, et al.
    Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010; 28: 4935–44.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords